AstraZeneca’s Liver Cancer Treatment Combo Accepted for US Priority Review
Tremelimumab, in conjunction with Imfinzi, has been accepted under priority review for patients with unresectable liver cancer in the United
Read more
Latest
FDA Approves Bristol Myers’ Opdualag for Unresectable or Metastatic Melanoma
American multinational pharmaceutical company Bristol Myers Squibb has announced that OpdualagTM , a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as one intravenous infusion,
Read more
Oragenics Announces Positive Data on Intranasal COVID-19 Vaccine Candidate
American biotech Oragenics, Inc. announced on Thursday the posting of a preprint manuscript in bioRxiv (pronounced “bio-archives”) evaluating a novel
Read more
Moderna Starts HIV Vaccine Trial that Uses Breakthrough mRNA Technology
The first doses of an experimental HIV vaccine antigen have been provided in a clinical study at George Washington University
Read more
Moderna’s ‘Spikevax’ COVID-19 Vaccine Gets Full FDA Approval
The U.S. Food and Drug Administration (FDA) has approved a second COVID-19 vaccine developed by Moderna, which will be marketed
Read more
Pfizer and BioNTech Launch Omicron-specific COVID Vaccine Trial
Pfizer and BioNTech announced on Tuesday that a clinical trial in healthy people 18 to 55 years old to assess
Read more
Abecma Becomes the First CAR T Cell Therapy Approved for Multiple Myeloma in Japan
Based on data obtained from Phase II and the Phase I studies, Abecma has received approval in Japan for the
Read more
Ori Biotech Raises €88M to Automate Cell Therapy Manufacture
Ori Biotech, based in the United Kingdom, has secured €88 million ($100 million) in its Series B funding to help
Read more
Evotec Wins € 7.5 Mill Grant for Development of First-in-class COVID-19 Therapeutic
Evotec, a publicly listed drug discovery and development company, has won a € 7.5 million grant for the development of
Read more
Pfizer’s COVID-19 Antiviral PAXLOVID Approved by UK Regulator
Pfizer’s COVID-19 Antiviral, PAXLOVID, has been authorised for use in people over 18 with mild to moderate COVID-19 and at
Read more